The Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released findings from a review of the Centers for Medicare & Medicaid Services’ (CMS) oversight of compounded drugs in Medicare Part D, identifying critical data limitations that undermine program integrity and patient safety. The review found that CMS lacks full visibility into the ingredients of compounded… (Eisen, April 20, 2026) #Medicare Part D, #Opioids, #Prescription Drugs